Alerta

一种载QS-21的纳米佐剂及其制备方法和应用

Resumen de: CN121754661A

本发明涉及一种载QS‑21的纳米佐剂及其制备方法和应用。本发明的纳米佐剂利用生物可降解聚合物、胆固醇和阳离子脂质包载QS‑21通过O/W方式形成固体脂质颗粒，其具有良好的分散性，且表面带正电荷，可吸附带负电的抗原蛋白以制备纳米佐剂疫苗。本发明的纳米佐剂疫苗中的胆固醇可与QS‑21结合，能够更好的实现QS‑21的包载，提高纳米佐剂疫苗的安全性与稳定性，在预防病毒感染中具有广泛应用前景。

非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用

Resumen de: WO2025093041A1

An immunogenic fragment of African swine fever virus CD2v protein, a recombinant protein, an immunogenic composition, and a use thereof. The provided immunogenic fragment of African swine fever virus CD2v protein or a variant thereof with immunogenicity can greatly improve the expression quantity while retaining the strong immunocompetence.

OMVs@Se生物活性制剂、制备方法及应用

Resumen de: CN121754500A

本发明公开了一种OMVs@Se生物活性制剂、其制备方法及应用。该制剂通过将硒纳米颗粒包覆于细菌外膜囊泡形成内核‑外壳结构，实现靶向递送至肺部巨噬细胞，有效抑制其铁死亡，并协同调控炎症反应，增强免疫清除能力，从而对细菌性肺炎发挥高效免疫治疗作用。

一种负载miR-424与氧化铈的植物外囊泡复合体及其制备方法和应用

Resumen de: CN121754504A

本发明公开了一种负载miR‑424与氧化铈的植物外囊泡复合体及其制备方法和应用，属于生物医药与纳米材料技术领域。所述复合体包含从葛根中提取的植物外囊泡以及负载于其内部的miR‑424与氧化铈纳米颗粒的复合物。其制备方法主要包括：从葛根中提取植物外囊泡；将氧化铈纳米颗粒与miR‑424按质量比复合；再将所得复合物与植物外囊泡共孵育实现负载。本发明提供的复合体兼具了植物外囊泡良好的生物相容性、miR‑424的基因调控功能以及氧化铈纳米颗粒的抗氧化活性，在低浓度下细胞毒性低，且对巨噬细胞显示较好的摄取倾向。该复合体可用于制备药物，尤其在炎症或氧化应激相关疾病（如脓毒症、急性肺损伤）的预防或治疗中具有应用潜力。

一种HPV治疗性mRNA疫苗及其制备方法与应用

Resumen de: CN121759492A

本发明涉及治疗性核酸疫苗领域，公开了一种可适用于多种人乳头瘤病毒（HPV）型别感染相关癌前病变和肿瘤的治疗性mRNA疫苗的设计策略。所述mRNA自N端至C端依次编码包括膜导向肽与HPV去致癌化的E6和E7抗原，二者可直接连接或通过1‑20个氨基酸的柔性接头连接。所述mRNA可由多种递送系统递送，疫苗在小鼠模型中诱导强效持久的细胞免疫和体液免疫；该策略适用于多种HPV高危型感染引起的宫颈、阴道、肛门等部位高级别鳞状上皮内病变及恶性肿瘤的治疗。

一种载MPLA-QS-21复合纳米佐剂、制备方法及其应用

Resumen de: CN121754660A

本发明涉及一种载MPLA‑QS‑21的聚合物固体脂质复合纳米佐剂及其制备方法和在病毒感染预防中的应用，该载MPLA‑QS‑21的聚合物脂质复合纳米佐剂为包载MPLA及QS‑21且以聚乳酸类可降解聚合物、胆固醇和阳离子脂质为材料通过O/W方式形成的固体脂质球形纳米颗粒，在该纳米颗粒的表面通过静电吸附的方式携载抗原以形成纳米佐剂疫苗。本发明所涉及的载MPLA‑QS‑21的聚合物固体脂质复合纳米佐剂疫苗可促进抗原提呈细胞的活化，快速激活细胞免疫和体液免疫，分泌高水平的抗体及细胞因子，从而达到有效预防病毒感染性疾病的目的，是增强抗原免疫原性的有效递送系统。

工程化细菌外膜囊泡、其制备方法及应用

Resumen de: CN121754501A

本发明公开了一种工程化细菌外膜囊泡、其制备方法及应用，工程化细菌外膜囊泡包括细菌外膜囊泡和包覆在所述细菌外膜囊泡表面的DNA‑焦磷酸盐矿化层；所述DNA‑焦磷酸盐矿化层中的DNA含有A2适配体。本发明利用滚环扩增技术，以锚定于OMV表面的环状DNA为模板，在OMV表面原位合成DNA‑焦磷酸盐矿化层，形成一种有机‑无机杂化的智能涂层。该方法充分利用DNA序列的可编辑性，通过设计含A2适配体的模板，使所构建的矿化外层具备精准靶向巨噬细胞表面CD14蛋白的能力，进而驱动巨噬细胞向M1表型极化，在实现高效肿瘤免疫治疗的同时，具有方法简单、高效且生物相容性高的显著优势。

一种核酸分子及其应用

Resumen de: CN121759472A

本发明公开了一种核酸分子及其应用。所述核酸分子包含编码胰岛素样生长因子结合蛋白‑1的CDS的核酸序列，所述核酸序列如SEQ ID NO:2所示。本发明所述IGFBP‑1 mRNA LNP脂质纳米颗粒能够显著提高IGFBP‑1在外周血（血清）及肿瘤微环境（肿瘤间质液）中的蛋白含量、还能够显著增加CD8+T的抗肿瘤功能；在与肿瘤疫苗联合使用时，也可显著提高肿瘤疫苗的治疗效果，在肿瘤治疗领域具有广阔的应用前景。

用于预防猫传染性腹膜炎的多核苷酸分子组合物、嵌合多核苷酸分子和mRNA疫苗

Resumen de: CN121759482A

本申请涉及兽药技术领域，具体提供一种用于预防猫传染性腹膜炎的多核苷酸分子组合物、嵌合多核苷酸分子和mRNA疫苗。为克服现有技术中S蛋白全长抗原引发的ADE效应，本申请采用无ADE风险的FIPV N蛋白，并与筛选出的S蛋白特异性T细胞和B细胞表位组合。核心方案包括两类：一是包含编码N蛋白和S蛋白表位肽的分开多核苷酸组合物；二是编码N蛋白与S蛋白表位肽的单一嵌合多核苷酸。这些多核苷酸经密码子优化，并封装于脂质纳米颗粒（LNP）中制成疫苗。实验证明，该疫苗能协同激发强大免疫应答，在不引起ADE的前提下，将免疫猫的生存率从基准的40%显著提升至80%‑100%，有效预防FIP。

Nanostructure comprising peroxidase mimetics glucose oxidases and particles with Photothermal effect

Resumen de: KR20260043180A

본 출원의 과산화효소 모방 효소, 포도당 산화효소 및 광열효과를 갖는 입자를 포함하는 나노 구조체는 암 예방 또는 치료용 약학적 조성물로 활용될 수 있다.

수지상 세포 표적화 나노-전달을 위한 방법 및 조성물

Resumen de: US20260014089A1

The present disclosure relates to novel compounds, methods, and cell-targeting formulations, e.g., a lipid nanoparticle (LNP) for targeted delivery to a tissue or a cell type. The compound and formulation provided herein are designed to have a targeting moiety configured to provide selective delivery features for the formulation and a lipid tail for being incorporated into the bilayer membrane of the formed lipid nanoparticle.

COMPOSITION COMPRISING SELECTIVE ORGAN TARGETING LIPID

Resumen de: KR20260043575A

본 발명은 특정 조직, 특히 비장 또는 면역 세포에 치료 분자를 정확하게 전달할 수 있는, 지질 나노입자(LNP)에 선택적 장기 표적 지질(Selective Organ Targeting lipid, SORT lipid)을 부가한 조성물에 관한 것으로, 전달 효율 및 체내 안정성이 우수하여 핵산 치료제 관련 기술 분야에 유용하게 사용할 수 있다.

MXene Tumor-targeting surface-modified MXene nanoparticles and method for preparing the same

Resumen de: KR20260043428A

본 발명은 종양 표적화 표면 개질된 MXene 나노 입자 및 이의 제조 방법에 관한 것으로, 광열제인 MXene에 종양 표적화를 위한 RGD 펩타이드를 결합하여 치료 효율성을 높이고, 나노 크기의 MXene 입자를 이용하여, 투과성 및 광열 치료 효과를 향상시키고, 생체 독성 및 생물 안정성을 높일 수 있다. 또한, RGD 펩타이드가 결합된 표면 개질된 MXene 나노 입자로, 종양 선택성을 부여하여 정상 세포와 구분하여 종양에 우선적으로 부착할 수 있다.

조작된 페닐알라닌 암모니아 리아제 (PAL)를 포함하는 관능화된 조성물

Resumen de: AU2024289116A1

The present invention relates to a composition comprising a solid carrier, an engineered phenylalanine ammonia lyase or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the engineered phenylalanine ammonia lyase or a fragment thereof by embedding the engineered phenylalanine ammonia lyase or a fragment thereof, and a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group. The present invention also relates to methods of producing said composition and uses thereof.

生产包含亲脂性化合物的水性介孔颗粒组合物的新方法

Resumen de: AU2024309710A1

Described is a method for the preparation of an aqueous mesoparticle composition comprising a lipophilic compound, comprising the steps of: a. Providing an emulsifier or a blend of emulsifiers in powder form; b. Mixing one or more oils at a temperature above 40°C where all oils have become liquid, wherein said oils differ in melting temperature and which mixture comprises at least a sufficient amount of medium chain triglycerides to enable the composition formed in step g have a partly liquid oil phase at temperatures around about 4°C; c. Adding the hydrophobic or amphiphilic compound in any hydrophobic solvent to the oil mixture; d. Optionally letting the mixture cool down to room temperature; e. Adding the emulsifier powder and water to the oil mixture and letting the mixture emulsify, under optional agitation and heating to 30-40°C; f. Subjecting the emulsified mixture to a sonication and optionally mixing or fluidisation treatment until the average particle size of the mixture remains stable; g. Cooling down the sonicated mixture allowing sufficient time for crystallisation; and h. Optionally, a second sonication treatment while keeping the mixture cold and compositions produced by the above method.

Preparation method of nanogels for gene delivery nanogel for delivering genetic material prepared by the method and use thereof

Resumen de: WO2026063696A1

The present invention relates to a method for preparing a genetic material delivery nanogel, which is based on a positively charged polymer-naturally derived polymer-phenol compound copolymer, the method comprising the steps of: (1) introducing a carboxylic acid or amine group-containing phenol compound into a naturally derived polymer so as to prepare a naturally derived polymer-phenol compound copolymer, which is amide-bonded and cross-linkable; and (2) introducing a positively charged polymer or material into the naturally derived polymer-phenol compound copolymer of step (1) so as to prepare a positively charged polymer-naturally derived polymer-phenol compound copolymer, which is amide-bonded.

一种靶向M2型巨噬细胞的甘露糖修饰共递送脂质纳米粒子及其制备方法

Resumen de: CN121731242A

本发明公开了一种靶向M2型巨噬细胞的共递送脂质纳米粒子及其制备方法和应用，该脂质纳米粒子由可电离阳离子脂质、中性辅助脂质、胆固醇、含有二硫键的PEG化脂质、末端连接有甘露糖的PEG化脂质以及被包封的包含miR‑99b和SIRPα siRNA的核酸药物制备而成，其通过引入DSPE‑S‑S‑PEG3000实现肿瘤微环境谷胱甘肽响应性PEG脱落，并利用DSPE‑PEG2000‑甘露糖实现基于CD206识别的主动靶向，从而高效、特异地将治疗性核酸共递送至M2型肿瘤相关巨噬细胞；本发明的纳米粒子能协同逆转M2巨噬细胞为M1抗肿瘤表型并阻断CD47‑SIRPα“别吃我”信号，有效重塑免疫抑制微环境，在肝细胞癌治疗中展现出卓越的肿瘤靶向能力、抑制肿瘤生长与转移以及促进抗肿瘤免疫应答的效果。

具有核酸负载物和可电离脂质的脂质纳米颗粒

Resumen de: WO2025046121A1

Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least an ionizable lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the ionizable lipid fraction comprises at least one ionizable glycerol dialkyl glycerol tetraether (GDGT) lipid. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine. In a further aspect, the invention relates to the ionizable GDGT lipids and methods for producing them.

编码CRISPR相关蛋白的核酸及其应用

Resumen de: WO2025045247A1

Provides are artificial nucleic acids, in particular RNA. A composition and kit of parts comprising the same are also provided.

提高姜黄素生物利用率的方法及制剂

Resumen de: CN121731246A

本发明涉及生物医药技术领域，具体涉及提高姜黄素生物利用率的方法及制剂。本发明通过碱性条件下制备姜黄素溶液/载体溶液，以及优化壁材的组成，形成碱性芯材‑复合壁材‑均质稳定‑喷雾干燥的一体化微囊制剂工艺，可实现姜黄素的高效包埋与稳定递送；制备工艺简单，能耗低，生产成本低，适合大规模生产与应用；本发明提供的姜黄素微胶囊以“蛋白‑环糊精‑姜黄素”三元复合物作为内芯，以麦芽糊精作为壳层，粒径均匀的纳米颗粒，Zeta电位绝对值高，包埋率可高达到97‑99%，载药量达到9‑15%，极大提高姜黄素水溶性、适口性、储存稳定性、生物利用度，扩宽姜黄素在口服制剂的应用范围。

一种载药磁性多孔氧化铝复合材料及其制备方法和应用

Resumen de: CN121731245A

本发明属于材料科学与生物医药技术领域，更具体地说是涉及一种载药磁性多孔氧化铝复合材料及其制备方法和应用。本发明将磁性纳米颗粒与多柔比星混合，得到悬浮液；将纳米多孔阳极氧化铝浸于悬浮液，干燥后在表面涂覆壳聚糖溶液，烘干后得到载药磁性多孔氧化铝复合材料。该载药磁性多孔氧化铝复合材料具有磁响应能力和可控门控性能，使药物释放方式由传统的被动扩散转变为外界可调控的按需释放，显著提高了释放过程的时间、空间和剂量精确度。

一种装载抑癌蛋白mRNA的靶向肿瘤的脂质纳米颗粒的制备方法

Resumen de: CN121731243A

本发明公开了一种装载抑癌蛋白mRNA的靶向肿瘤的脂质纳米颗粒的制备方法，其步骤包括：（1）将SM102，DSPC，β‑sitosterol，DMG‑PEG2K，DSPE‑PEG2k‑RGD分别溶于无水乙醇，制成母液；（2）按比例量取各组分的母液，混合配制成有机相；（3）将抑癌蛋白mRNA溶于柠檬酸钠缓冲液中，制成水相；（4）有机相和水相通过微流控反应，合成脂质纳米颗粒。还公开了相应的脂质纳米颗粒及应用。本发明在脂质纳米颗粒中设计具有靶向Integrin αVβ3受体阳性肿瘤细胞的靶向肽，使该纳米颗粒可以精准靶向至Integrin αVβ3受体阳性肿瘤细胞；通过脂质纳米颗粒的成分改造与配方优化，实现脂质纳米颗粒对肿瘤细胞的较高转染效率，最终实现促进肿瘤细胞凋亡的抗肿瘤治疗功效。

用于向组织广泛递送RNA的组合物和方法

Resumen de: WO2025049632A1

The present invention relates to lipid nanoparticle (LNP) compositions, and diagnostic or therapeutic polynucleotides, e.g. TERT mRNA, which may be delivered with the LNP compositions in formulations to various tissues and cell types throughout the mammalian body, including stem cells, progenitor cells, germ cells, differentiated cells, or terminally differentiated cells, cancer cells, endothelial cells, epithelial cells, spleen cells, hepatocytes, kidney cells and/or bone cells, e.g., for the diagnosis, prevention and/or treatment of conditions or disease.

pH诱导的结构转换脂质纳米载体、半合成细胞外囊泡、其制备方法及应用

Resumen de: WO2025052244A1

The present disclosure provides a pH-inducible structure-switching non-lamellar lipid nanovector (LNV) comprising: (a) at least one ionizable cationic lipid; (b) at least one phospholipid displaying a critical packing parameter (CPP) value > 1; and (c) at least one non-ionic surfactant displaying a CPP value < 1 at a molar concentration of between 20 % and 50 %, a method of making the LNV, a semi-synthetic extracellular vesicle (ssEV) resulting from the fusion of the LNV with extracellular vesicles at a pH higher than 6 and up to about 10, a kit and a use of the ssEV as a medicament or diagnostic agent.

一种磷酸芦可替尼纳米结构脂质载体及其制备方法和应用、磷酸芦可替尼组合物

Nº publicación: CN121731481A 27/03/2026

Solicitante:

山东诺明康药物研究院有限公司

Resumen de: CN121731481A

本发明提供了一种磷酸芦可替尼纳米结构脂质载体及其制备方法和应用、磷酸芦可替尼组合物，属于药物制剂技术领域。本发明提供的磷酸芦可替尼纳米结构脂质载体和磷酸芦可替尼组合物，通过固态脂质和液态脂质复配以及引入抗晶化剂，将磷酸芦可替尼包封于由固态脂质和液态脂质构成的纳米结构脂质载体核心内，解决了磷酸芦可替尼的吡唑结构导致的独特析晶问题，具有包封率高、稳定性好的优势。本发明还将磷酸芦可替尼纳米结构脂质载体均匀分散于皮肤病学可接受的基质中，得到包含治疗有效量的磷酸芦可替尼组合物，该组合物表现出显著增强的药物稳定性和皮肤滞留能力，降低系统暴露风险。